NEXT Oncology and Virginia Cancer Specialists have joined forces, launching NEXT Virginia, a cancer clinic, in September 2021. This partnership will also help expand VCS’s phase I and developmental therapeutics cancer research program and bring the latest in new agents and anticancer treatments to the VCS Research Institute. The expanded...

Joint venture brings access to proprietary Phase I program to more patients (SAN ANTONIO) October 5, 2021 –– Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, has entered into a joint venture with Virginia Cancer Specialists (VCS). Dr. Alex Spira of VCS sought to expand the clinic’s Phase I...

Nicole Villalpando Austin American-Statesman - view article Research infusion nurse, Jasmine Warner checks vital signs of cancer patient Kimberly Gibbs at NEXT Oncology. Gibbs is undergoing treatment for ovarian cancer and travels from outside Tulsa, Oklahoma. NEXT Oncology is bringing phase one clinical cancer treatment trials to Austin for the...

Next Oncology is advancing plans to expand its clinical trials facilities footprint nationally and internationally despite a global health crisis impacting that timeline. The San Antonio-based cancer research company has recently opened the first such facility outside of its headquarters home and already has other centers in various stages of...

Last month, the FDA granted accelerated approval of sotorasib (Lumakras) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following the results of the phase II CodeBreaK 100 trial, data from which were presented during the recent virtual American Society of Clinical Oncology annual meeting. In this second of four exclusive episodes, MedPage...

— Our expert roundtable discusses how they the treat NSCLC patients who are waiting on NGS results Next-generation sequencing (NGS) is recommended by the National Comprehensive Cancer Network (NCCN) for all patients with non-small cell lung cancer (NSCLC). Several studies at the recent American Society of Clinical Oncology virtual annual meeting explored...

At the recent virtual American Society of Clinical Oncology annual meeting, results of the phase III IMpower010 trial demonstrated that adjuvant atezolizumab (Tecentriq) for patients with stage IB to IIIA non-small cell lung cancer (NSCLC) improved disease-free survival in patients with high PD-L1 expression. In this first of four exclusive episodes, MedPage Today brought together three...

Dr. Anthony Tolcher’s dedication to medical advancements and innovative approaches at NEXT Oncology has earned the practice Best Oncologist in San Antonio in the 2021 Readers’ Choice Awards. NEXT Oncology has made strides in patient care, especially over the past year. As a Phase 1 research center, patient safety is...